2019
1092 – Importance of Endoscopic and Histological Evaluation in the Management of Immune Checkpoint Inhibitor-Induced Colitis
Abu-Sbeih H, Ali F, Luo W, Raju G, Wang Y. 1092 – Importance of Endoscopic and Histological Evaluation in the Management of Immune Checkpoint Inhibitor-Induced Colitis. Gastroenterology 2019, 156: s-232-s-233. DOI: 10.1016/s0016-5085(19)37377-9.Peer-Reviewed Original Research
2018
Outcomes of Vedolizumab Treatment in Patients With Immune Checkpoint Inhibitor-Induced Diarrhea and Colitis: A Multi-Center Study
Abu-Sbeih H, Ali F, Alsaadi D, Jennings J, Luo W, Gong Z, Richards D, Charabaty A, Wang Y. Outcomes of Vedolizumab Treatment in Patients With Immune Checkpoint Inhibitor-Induced Diarrhea and Colitis: A Multi-Center Study. The American Journal Of Gastroenterology 2018, 113: s58. DOI: 10.14309/00000434-201810001-00110.Peer-Reviewed Original ResearchThe Importance of Endoscopic and Histological Evaluation in the Management of Immune Checkpoint Inhibitor-Induced Colitis
Abu-Sbeih H, Ali F, Luo W, Raju G, Wang Y. The Importance of Endoscopic and Histological Evaluation in the Management of Immune Checkpoint Inhibitor-Induced Colitis. The American Journal Of Gastroenterology 2018, 113: s112-s113. DOI: 10.14309/00000434-201810001-00197.Peer-Reviewed Original Research